Westminster Health Forum

Since lockdown, we have been organising our full programme of conferences online. We will continue online until further notice, to ensure we play our part in helping our employees and delegates to remain safe during this time. We are pleased that so many key stakeholders, policymakers and other interested parties - both old friends and new delegates - are taking up the opportunity to discuss public policy issues and network at our impartial seminars. New events are coming on to our conference programme all the time. So there are plenty of opportunities for you to join us if you haven’t already, from wherever you are. For booking-related queries, or information on speaking, please email us at info@forumsupport.co.uk or contact us using one of the following numbers: +44 (0)7951044809 / +44 (0)7503591880 / +44 (0)7538736244.
For delegates already booked on, we will send you the online joining instructions (including links, event numbers and passwords) five working days before your conference. If you cannot find these in your inbox please email delegate.relations@forumsupport.co.uk

Next steps for antimicrobial resistance - funding and incentives, prescribing, developing the global response and learning from the COVID-19 pandemic

Morning, Monday, 30th November 2020

Online Conference

***Full-scale policy conference taking place online***

This conference will discuss priorities for tackling antimicrobial resistance, progress on the UK strategy and global collaboration.

It takes place following the launch of a new payment model for antibiotics earlier this year which incentivises pharmaceutical companies to develop innovative new treatments.

The discussion at a glance:

  • priority areas for research and development in AMR - in light of new financial incentives for the industry
  • new DHSC payment system - as well as the role of regulation in accelerating development and uptake of new treatments
  • COVID-19:
    • the impact on AMR research systems
    • collaboration - what can be learned from examples of joint-working during the pandemic
    • recovery plans - priorities for integrating tackling AMR and build on work being undertaken in local health systems.

The agenda:

  • Priorities for innovation and global collaboration in tackling antimicrobial resistance
  • Trends in global antibiotic use - time for increased AWaRe-ness and ambition?
  • The impact of COVID-19 on antimicrobial resistance research systems and advancing innovation
  • Next steps for enabling the development and adoption of innovation and new treatments
  • Funding and opportunities for accelerating clinical research and it reaching patients
  • The new payment system - prospects and priorities for incentivising the development of new antibiotic treatments
  • Progress in prescribing and tackling antimicrobial resistance in the UK
  • Improving prevention and understanding the impact of COVID-19
  • Applying lessons from AMR in animal and environmental health and opportunities for collaboration
  • Responsible antibiotic use in healthcare - integration with COVID-19 recovery plans, diagnostics and appropriate prescribing, supporting clinicians and patients, local health system implementation

A scan of relevant developments:

  • the National Institute for Health Protection (NIHP) - bringing together PHE and NHS Test and Trace, as well as the analytical capability of the JBC under a single leadership team
  • the new DHSC payment model for antibiotics:
    • where pharmaceutical companies are paid up front for developing new antibiotics as a way of incentivising the development of innovative treatments
    • with payment being based on the value it provides instead of the amount consumed
  • the AMR Action Fund - launched by pharmaceutical companies around the world to tackle AMR
  • DHSC’s UK 5-year action plan for antimicrobial resistance 2019 to 2024 - including areas such as optimising prescribing, utilising data, improving education and training, and public engagement
  • the PHE infectious diseases strategy - for 2020 and 2025 with plans for the allocation of resources and tackling infectious diseases

The discussion in detail:  

International collaboration

  • assessing the global health response to tackling COVID-19
  • opportunities for tackling antimicrobial resistance as part of the fight against the pandemic
  • what can be learnt from the global collaboration for COVID-19 that can be transferred to AMR

Research and innovation

  • COVID-19 - the impact of tackling the pandemic on antimicrobial research systems
  • priority areas for driving forward innovation
  • regulation - opportunities for supporting and speeding up the adoption of new innovative treatment and methods
  • assessing new funding models - prospects for getting innovative clinical research adopted and bringing forward new antibiotics to benefit patients, looking at:
    • the new DHSC government payment system in making the development of new antibiotics more attractive to the pharmaceutical industry
    • the international AMR Action Fund


  • the NIHP - its role and scope, and how it will work with partners across the health system
  • building on PHE’s Infectious Disease Strategy 2020-25 - which made becoming a world leader in tackling antimicrobial resistance a strategic priority
  • learning from the COVID-19 response - for responses to future infectious diseases

Promoting the responsible use of antibiotics in healthcare

  • responsible use of antibiotics in healthcare - progress and next steps in the context of the UK 5-year action plan
  • encouraging the appropriate use of antibiotics:
    • increasing patient awareness of AMR
    • engaging with clinicians to reduce antibiotic use to inform appropriate prescribing, including through provision of training
    • improving diagnostic testing of infections and utilising data
  • tackling antimicrobial resistance across local health systems:
    • implementation strategies
    • the role of antimicrobial stewardships and taking a system-wide approach in preserving antimicrobials
    • using COVID-19 recovery plans as an opportunity to integrate tackling AMR in local health systems going forward
  • animal and environmental health - assessing progress, how lessons learned can be applied to human health, and opportunities for collaboration among sectors

Policy officials attending:

Our forums are known for attracting strong interest from policymakers and stakeholders. Places have been reserved by officials from the Department of Health; DAERA; the Medicines and Healthcare products Regulatory Agency; and the Scottish Government. Also due to attend are representatives from Innovate UK; Juvabis AG; Pfizer; University of Exeter; and University of Strathclyde.

A press pass has been reserved by a representative from: APM Health Europe.

This is a full-scale conference taking place online***

  • full, four-hour programme including comfort breaks - you’ll also get a full recording to refer back to
  • information-rich discussion involving key policymakers and stakeholders
  • conference materials provided in advance, including speaker biographies
  • speakers presenting via webcam, accompanied by slides if they wish, using the Cisco WebEx professional online conference platform (easy for delegates - we’ll provide full details)
  • opportunities for live delegate questions and comments with all speakers
  • a recording of the addresses, all slides cleared by speakers, and further materials, is made available to all delegates afterwards as a permanent record of the proceedings
  • delegates are able to add their own written comments and articles following the conference, to be distributed to all attendees and more widely
  • networking too - there will be opportunities for delegates to e-meet and interact - we’ll tell you how!

Full information and guidance on how to take part will be sent to delegates before the conference

Keynote Speaker

Professor Dame Sally Davies

UK Government Special Envoy on Antimicrobial Resistance and former Chief Medical Officer for England

Keynote Speakers

Dr Bryan Deane

New Medicines and Data Policy Director, ABPI

Professor Dame Sally Davies

UK Government Special Envoy on Antimicrobial Resistance and former Chief Medical Officer for England

Professor Mike Sharland

Professor in Paediatric Infectious Diseases, St George's University London and Chair, WHO EML Antibiotic Working Group

Silas Holland

Interim Head of External Affairs, AMR Action Fund

Professor Peter Wilson

Consultant Microbiologist, University College London Hospitals NHS Foundation Trust; and Member, Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection

Dr Kitty Healey

Head, Antimicrobial Resistance Policy and Surveillance, Veterinary Medicines Directorate, Defra


Kevin Hollinrake MP


Lucy Watson

Chair, The Patients Association

Dr Matthew Inada-Kim

Consultant Acute Physician, Hampshire Hospitals NHS Foundation Trust

Professor Chris Butler

General Practitioner and Professor of Primary Care, Nuffield Department of Primary Care Health Sciences, University of Oxford